Chemoprevention of colorectal cancer in inflammatory bowel disease

References

• American Cancer Society. Colorectal cancer facts and figures 2014–2016. Atlanta: American Cancer Society; 2014.
   Google Scholar
• Lewis JD, Deren JJ, Lichtenstein GR. Cancer risk in patients with inflammatory bowel disease. Gastroenterol Clin North Am. 1999;28(2):459–477.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91(4):854–862. DOI:10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z
   PubMed Web of Science ®Google Scholar
• Jess T, Simonsen J, Jørgensen KT, et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143(2):375–381.e1; quiz e13–e14. DOI:10.1053/j.gastro.2012.04.016
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr. Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol Clin North Am. 2006;35(3):517–531. pii:S0889-8553(06)00039-2.
   PubMed Web of Science ®Google Scholar
• Velayos FS, Loftus EV Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology. 2006;130(7):1941–1949. pii:S0016-5085(06)00600-7.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015;372(15):1441–1452. DOI:10.1056/NEJMra1403718
   PubMed Web of Science ®Google Scholar
• Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res. 2009;29(7):2727–2737. pii:29/7/2727.
   PubMed Web of Science ®Google Scholar
• Clevers H. Colon cancer–understanding how NSAIDs work. N Engl J Med. 2006;354(7):761–763. pii:354/7/761.
   PubMed Web of Science ®Google Scholar
• Roessner A, Kuester D, Malfertheiner P, et al. Oxidative stress in ulcerative colitis-associated carcinogenesis. Pathol Res Pract. 2008;204(7):511–524. DOI:10.1016/j.prp.2008.04.011
   PubMed Web of Science ®Google Scholar
• Fantini MC, Pallone F. Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets. 2008;9(5):375–380.
   PubMed Web of Science ®Google Scholar
• Atreya R, Neurath MF. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol. 2005;28(3):187–196. pii:CRIAI:28:3:187.
   PubMed Web of Science ®Google Scholar
• Schottelius AJ, Dinter H. Cytokines, NF-kappaB, microenvironment, intestinal inflammation and cancer. Cancer Treat Res. 2006;130:67–87.
   PubMedGoogle Scholar
• Tang W, Wang W, Zhang Y, et al. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced chemokine release in both TRAIL-resistant and TRAIL-sensitive cells via nuclear factor kappa B. FEBS J. 2009;276(2):581–593. DOI:10.1111/j.1742-4658.2008.06809.x
   PubMed Web of Science ®Google Scholar
• Yan B, Wang H, Rabbani ZN, et al. Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation. Cancer Res. 2006;66(24):11565–11570. pii:66/24/11565.
   PubMed Web of Science ®Google Scholar
• Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323(18):1228–1233. DOI:10.1056/NEJM199011013231802
   PubMed Web of Science ®Google Scholar
• Ekbom A, Helmick C, Zack M, et al. Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet. 1990;336(8711):357–359. pii:0140-6736(90)91889-I.
   PubMed Web of Science ®Google Scholar
• Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526–535.
   PubMed Web of Science ®Google Scholar
• Lyakhovich A, Gasche C. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol Ther. 2010;31(2):202–209. DOI:10.1111/j.1365-2036.2009.04195.x
   PubMed Web of Science ®Google Scholar
• Luciani MG, Campregher C, Fortune JM, et al. 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology. 2007;132(1):221–235. pii:S0016-5085(06)02239-6.
   PubMed Web of Science ®Google Scholar
• Gasche C, Goel A, Natarajan L, et al. Mesalazine improves replication fidelity in cultured colorectal cells. Cancer Res. 2005;65(10):3993–3997. pii:65/10/3993.
   PubMed Web of Science ®Google Scholar
• Joshi R, Kumar S, Unnikrishnan M, et al. Free radical scavenging reactions of sulfasalazine, 5-aminosalicylic acid and sulfapyridine: mechanistic aspects and antioxidant activity. Free Radic Res. 2005;39(11):1163–1172. pii:X73126802R3M5604.
   PubMed Web of Science ®Google Scholar
• Fina D, Franchi L, Caruso R, et al. 5-Aminosalicylic acid enhances anchorage-independent colorectal cancer cell death. Eur J Cancer. 2006;42(15):2609–2616. pii:S0959-8049(06)00547-8.
   PubMed Web of Science ®Google Scholar
• Horváth K, Varga C, Berkó A, et al. The involvement of heme oxygenase-1 activity in the therapeutic actions of 5-aminosalicylic acid in rat colitis. Eur J Pharmacol. 2008;581(3):315–323. DOI:10.1016/j.ejphar.2007.12.004
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Shishodia S, Sandur SK, et al. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72(11):1605–1621. pii:S0006-2952(06)00389-3.
   PubMed Web of Science ®Google Scholar
• Stolfi C, Fina D, Caruso R, et al. Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase. Carcinogenesis. 2008;29(6):1258–1266. DOI:10.1093/carcin/bgn122
   PubMed Web of Science ®Google Scholar
• Joo K, Lee Y, Choi D, et al. An anti-inflammatory mechanism of taurine conjugated 5-aminosalicylic acid against experimental colitis: taurine chloramine potentiates inhibitory effect of 5-aminosalicylic acid on IL-1beta-mediated NFkappaB activation. Eur J Pharmacol. 2009;618(1–3):91–97. DOI:10.1016/j.ejphar.2009.07.009
   PubMed Web of Science ®Google Scholar
• Mutoh M, Niho N, Komiya M, et al. Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice. Carcinogenesis. 2008;29(4):824–829. DOI:10.1093/carcin/bgn028
   PubMed Web of Science ®Google Scholar
• Bos CL, Diks SH, Hardwick JC, et al. Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis. 2006;27(12):2371–2382. pii:bgl071.
   PubMed Web of Science ®Google Scholar
• Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005;201(8):1205–1215. pii:jem.20041948.
   PubMed Web of Science ®Google Scholar
• Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther. 2006;24(Suppl 1):2–9. pii:APT3069.
   PubMed Web of Science ®Google Scholar
• Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100(6):1345–1353. pii:AJG41442.
   PubMed Web of Science ®Google Scholar
• van Staa TP, Card T, Logan RF, et al. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54(11):1573–1578. pii:gut.2005.070896.
   PubMed Web of Science ®Google Scholar
• Tang J, Sharif O, Pai C, et al. Mesalamine protects against colorectal cancer in inflammatory bowel disease. Dig Dis Sci. 2010;55(6):1696–1703. DOI:10.1007/s10620-009-0942-x
   PubMed Web of Science ®Google Scholar
• Zhao L-N, Li J-Y, Yu T, 5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysis. PLoS One. 2014;9(4):e94208. DOI:10.1371/journal.pone.0094208
   PubMed Web of Science ®Google Scholar
• Jess T, Loftus EV Jr, Velayos FS, et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol. 2007;102(4):829–836. pii:AJG1070.
   PubMed Web of Science ®Google Scholar
• Terdiman JP, Steinbuch M, Blumentals WA, et al. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(4):367–371. DOI:10.1002/ibd.20074
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Gulamhusein A, Bernstein CN. 5-Aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol. 2012;107(9):1298–1304; quiz 1297, 1305. DOI:10.1038/ajg.2012.198
   Web of Science ®Google Scholar
• Bernstein CN, Nugent Z, Blanchard JF. 5-Aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol. 2011;106(4):731–736. DOI:10.1038/ajg.2011.50
   PubMed Web of Science ®Google Scholar
• Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis. 2013;7(1):1–33. DOI:10.1016/j.crohns.2012.09.005
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Sachar DB. Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501–523; quiz 524. DOI:10.1038/ajg.2009.727
   PubMed Web of Science ®Google Scholar
• Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43(4):329–339.
   PubMed Web of Science ®Google Scholar
• Thomas CW, Myhre GM, Tschumper R, et al. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther. 2005;312(2):537–545. DOI:10.1124/jpet.104.074815
   PubMed Web of Science ®Google Scholar
• Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111(8):1133–1145. DOI:10.1172/JCI16432
   PubMed Web of Science ®Google Scholar
• Chalmers AH. Studies on the mechanism of formation of 5-mercapto-1-methyl-4-nitroimidazole, a metabolite of the immunosuppressive drug azathioprine. Biochem Pharmacol. 1974;23(13):1891–1901. pii:0006-2952(74)90198-1.
   PubMed Web of Science ®Google Scholar
• Burchenal JH, Murphy ML, Ellison RR, et al. Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood. 1953;8(11):965–999.
   PubMed Web of Science ®Google Scholar
• Murray JE, Merrill JP, Harrison JH, et al. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med. 1963;268:1315–1323. DOI:10.1056/NEJM196306132682401
   PubMed Web of Science ®Google Scholar
• Derijks LJ, Gilissen LP, Hooymans PM, et al. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24(5):715–729. pii:APT2980.
   PubMed Web of Science ®Google Scholar
• Lopez A, Mounier M, Bouvier A-M, et al. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12(8):1324–1329. DOI:10.1016/j.cgh.2014.02.026
   PubMed Web of Science ®Google Scholar
• Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013;145(5):1007–1015.e3. DOI:10.1053/j.gastro.2013.07.035
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Blonski W, Diamond RH, et al. Hepatosplenic T-cell lymphoma in inflammatory bowel disease: a possible thiopurine-induced chromosomal abnormality. Am J Gastroenterol. 2010;105(10):2299–2301. DOI:10.1038/ajg.2010.213
   PubMed Web of Science ®Google Scholar
• Singh H, Nugent Z, Demers AA, et al. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology. 2011;141(5):1612–1620. DOI:10.1053/j.gastro.2011.07.039
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141(5):1621–1628.e1-5. DOI:10.1053/j.gastro.2011.06.050
   PubMed Web of Science ®Google Scholar
• Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143(2):390–399.e1. DOI:10.1053/j.gastro.2012.05.004
   PubMed Web of Science ®Google Scholar
• Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol. 2010;105(7):1604–1609. DOI:10.1038/ajg.2009.745
   PubMed Web of Science ®Google Scholar
• Pasternak B, Svanström H, Schmiegelow K, et al. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol. 2013;177(11):1296–1305. DOI:10.1093/aje/kws375
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013;145(1):166–175.e8. DOI:10.1053/j.gastro.2013.03.044
   PubMed Web of Science ®Google Scholar
• Gong J, Zhu L, Guo Z, et al. Use of thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel diseases: a meta-analysis. PLoS One. 2013;8(11):e81487. DOI:10.1371/journal.pone.0081487
   PubMed Web of Science ®Google Scholar
• Jess T, Lopez A, Andersson M, et al. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. Clin Gastroenterol Hepatol. 2014;12(11):1793–1800.e1. DOI:10.1016/j.cgh.2014.05.019
   PubMed Web of Science ®Google Scholar
• Greten FR, Karin M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett. 2004;206(2):193–199. DOI:10.1016/j.canlet.2003.08.029
   PubMed Web of Science ®Google Scholar
• Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58(4):501–508. DOI:10.1136/gut.2008.163642
   PubMed Web of Science ®Google Scholar
• Baars JE, Looman CW, Steyerberg EW, et al. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol. 2011;106(2):319–328. DOI:10.1038/ajg.2010.428
   PubMed Web of Science ®Google Scholar
• Caspersen S, Elkjaer M, Riis L, et al. Infliximab for inflammatory bowel disease in Denmark 1999–2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol. 2008;6(11):1212–1217; quiz 1176. DOI:10.1016/j.cgh.2008.05.010
   PubMed Web of Science ®Google Scholar
• Nyboe Andersen N, Pasternak B, Basit S, et al. Association between tumor necrosis factor-alpha antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014;311(23):2406–2413. DOI:10.1001/jama.2014.5613
   PubMed Web of Science ®Google Scholar
• Martinez JD, Stratagoules ED, LaRue JM, et al. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer. 1998;31(2):111–118. DOI:10.1080/01635589809514689
   PubMed Web of Science ®Google Scholar
• Narisawa T, Fukaura Y, Terada K, et al. Prevention of N-methylnitrosourea-induced colon tumorigenesis by ursodeoxycholic acid in F344 rats. Jpn J Cancer Res. 1998;89(10):1009–1013. pii:S0910505098800707.
   PubMedGoogle Scholar
• Narisawa T, Fukaura Y, Terada K, et al. Inhibitory effects of ursodeoxycholic acid on N-methylnitrosourea-induced colon carcinogenesis and colonic mucosal telomerase activity in F344 rats. J Exp Clin Cancer Res. 1999;18(2):259–266.
   PubMed Web of Science ®Google Scholar
• Earnest DL, Holubec H, Wali RK, et al. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res. 1994;54(19):5071–5074.
   PubMed Web of Science ®Google Scholar
• Rigas B, Tsioulias GJ, Allan C, et al. The effect of bile acids and piroxicam on MHC antigen expression in rat colonocytes during colon cancer development. Immunology. 1994;83(2):319–323.
   PubMed Web of Science ®Google Scholar
• Ikegami T, Matsuzaki Y, Shoda J, et al. The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett. 1998;134(2):129–139. pii:S0304-3835(98)00248-1.
   PubMed Web of Science ®Google Scholar
• Alberts DS, Martínez ME, Hess LM, et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst. 2005;97(11):846–853. pii:97/11/846.
   PubMedGoogle Scholar
• Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56(1):48–54. pii:S0016510702000068.
   PubMed Web of Science ®Google Scholar
• Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Int Med. 2001;134(2):89–95. pii:200101160-00008.
   PubMed Web of Science ®Google Scholar
• Pardi DS, Loftus EV Jr, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003;124(4):889–893. DOI:10.1053/gast.2003.50156
   PubMed Web of Science ®Google Scholar
• Wolf JM, Rybicki LA, Lashner BA. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther. 2005;22(9):783–788. pii:APT2650.
   PubMed Web of Science ®Google Scholar
• Navaneethan U, Kochhar G, Venkatesh PG, et al. Duration and severity of primary sclerosing cholangitis is not associated with risk of neoplastic changes in the colon in patients with ulcerative colitis. Gastrointest Endosc. 2012;75(5):1045–1054.e1. DOI:10.1016/j.gie.2012.01.015
   PubMed Web of Science ®Google Scholar
• Lindström L, Boberg KM, Wikman O, et al. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther. 2012;35(4):451–457. DOI:10.1111/j.1365-2036.2011.04966.x
   PubMed Web of Science ®Google Scholar
• Eaton JE, Silveira MG, Pardi DS, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol. 2011;106(9):1638–1645. DOI:10.1038/ajg.2011.156
   PubMed Web of Science ®Google Scholar
• Singh S, Khanna S, Pardi DS, et al. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2013;19(8):1631–1638. DOI:10.1097/MIB.0b013e318286fa61
   PubMed Web of Science ®Google Scholar
• Sjöqvist U, Tribukait B, Ost A, et al. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. Anticancer Res. 2004;24(5B):3121–3127.
   PubMed Web of Science ®Google Scholar
• Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51(2):660–678. DOI:10.1002/hep.23294
   PubMed Web of Science ®Google Scholar
• Wang D, DuBois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene. 2010;29:781–788. DOI:10.1038/onc.2009.421
   PubMed Web of Science ®Google Scholar
• Liu Y, Tang W, Wang J, et al. Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies. Cancer Causes Control. 2014 Feb;25(2):237–249. DOI:10.1007/s10552-013-0326-6
   PubMed Web of Science ®Google Scholar
• Final recommendation statement: aspirin use to prevent cardiovascular disease and colorectal cancer: preventive medication. U.S. Preventive Services Task Force. 2016 Nov. Available from: https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/aspirin-to-prevent-cardiovascular-disease-and-cancer
   Google Scholar
• Burr NE, Hull MA, Subramanian V. Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease? World J Gastroenterol. 2016 April 7;22(13):3679–3686. DOI:10.3748/wjg.v22.i13.3679
   PubMed Web of Science ®Google Scholar
• Samadder NJ, Mukherjee B, Huang S-C, et al. Risk of colorectal cancer in self-reported inflammatory bowel disease and modifications of risk by statin and NSAID use. Cancer. 2011 Apr 15;117(8):1640–1648. DOI:10.1002/cncr.25731
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Cagan A, Cai T, et al. Statin use is associated with reduced risk of colorectal cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2016;14:973–979. DOI:10.1016/j.cgh.2016.02.017
   PubMed Web of Science ®Google Scholar
• Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18(2):191–198. pii:1648.
   PubMed Web of Science ®Google Scholar
• Florholmen J. Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease. Scand J Gastroenterol. 2015;50(1):43–52. DOI:10.3109/00365521.2014.977943
   PubMed Web of Science ®Google Scholar